A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study
Epilepsia · 2024
DOI: 10.1111/epi.17843 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, 2024. Verfasst von Roberta Roberti und 36 weiteren Autor:innen. Beteiligte Einrichtung: Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy. Hauptthemen laut MEDLINE: Epilepsies, Partial, Epilepsy, Nitriles, Pyridones. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
There are few comparative data on the third‐generation antiseizure medications (ASMs). We aimed to assess and compare the effectiveness of brivaracetam (BRV), eslicarbazepine acetate (ESL), lacosamide (LCM), and perampanel (PER) in people with epilepsy (PWE). Efficacy and tolerability were compared as secondary objectives.
Methods
This multicenter, retrospective study collected data from 22 Italian neurology/epilepsy centers. All adult PWE who started add‐on treatment with one of the studied ASMs between January 2018 and October 2021 were included. Retention rate was established as effectiveness measure and described using Kaplan–Meier curves and the best fitting survival model. The responder status and the occurrence of adverse events (AEs) were used to evaluate efficacy and safety, respectively. The odds of AEs and drug efficacy were estimated by two multilevel logistic models.
Results
A total of 960 patients (52.92% females, median age = 43 years) met the inclusion criteria. They mainly suffered from structural epilepsy (52.29%) with monthly (46.2%) focal seizures (69.58%). Compared with LCM, all the studied ASMs had a higher dropout risk, statistically significant in the BRV levetiracetam (LEV)‐naïve (hazard ratio [HR] = 1.97, 95% confidence interval [CI] = 1.17–3.29) and PER groups (HR = 1.64, 95% CI = 1.06–2.55). Women were at higher risk of discontinuing ESL (HR = 5.33, 95% CI = 1.71–16.61), as well as PER‐treated patients with unknown epilepsy etiology versus those with structural etiology (HR = 1.74, 95% CI = 1.05–2.88). BRV with prior LEV therapy showed lower odds of efficacy (odds ratio [OR] = .08, 95% CI = .01–.48) versus LCM, whereas a higher efficacy was observed in women treated with BRV and LEV‐naïve (OR = 10.32, 95% CI = 1.55–68.78) versus men. PER (OR = 6.93, 95% CI = 3.32–14.44) and BRV in LEV‐naïve patients (OR = 6.80, 95% CI = 2.64–17.52) had a higher chance of AEs than LCM. Significance Comparative evidence from real‐world studies may help clinicians to tailor treatments according to patients' demographic and clinical characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy.
- Department of Neurology, Epilepsy Center, SS Annunziata Hospital, Chieti, Italy.
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Clinical Neurology, University of Genoa, Genoa, Italy.
- IRCSS Ospedale Policlinico San Martino, Genoa, Italy.
- Neurology Unit, Maggiore Hospital, ASST Lodi, Lodi, Italy.
- Department of Neurology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
ORCID-Profile: Francesca Anzellotti, Laura Canafoglia, Roberta Di Giacomo, Jacopo C DiFrancesco, Fedele Dono, Giovanni Falcicchio, Antonio Gambardella, Angelo Labate, Simona Lattanzi, Claudio Liguori, Annacarmen Nilo, Francesca Felicia Operto, Angelo Pascarella, Emilio Russo
Zitieren
APA
Roberti, R., Di Gennaro, G., Anzellotti, F., Arnaldi, D., Belcastro, V., Beretta, S., Boero, G., Bonanni, P., Canafoglia, L., D'Aniello, A., Dainese, F., De Caro, C., Di Gennaro, G., Di Giacomo, R., DiFrancesco, J. C., Dono, F., Falcicchio, G., Ferlazzo, E., Foschi, N., …, & Russo, E. (2024). A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study. Epilepsia. https://doi.org/10.1111/epi.17843
Vancouver
Roberti R, Di Gennaro G, Anzellotti F, Arnaldi D, Belcastro V, Beretta S, et al. A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study. Epilepsia. 2024. doi:10.1111/epi.17843
BibTeX
@article{Roberti2024,
author = {Roberti, Roberta and Di Gennaro, Gianfranco and Anzellotti, Francesca and Arnaldi, Dario and Belcastro, Vincenzo and Beretta, Simone and Boero, Giovanni and Bonanni, Paolo and Canafoglia, Laura and D'Aniello, Alfredo and Dainese, Filippo and De Caro, Carmen and Di Gennaro, Giancarlo and Di Giacomo, Roberta and DiFrancesco, Jacopo C and Dono, Fedele and Falcicchio, Giovanni and Ferlazzo, Edoardo and Foschi, Nicoletta and Franciotta, Silvia and Gambardella, Antonio and Giordano, Alfonso and Iannone, Luigi Francesco and Labate, Angelo and La Neve, Angela and Lattanzi, Simona and Leggio, Ugo and Liguori, Claudio and Maschio, Marta and Nilo, Annacarmen and Operto, Francesca Felicia and Pascarella, Angelo and Pauletto, Giada and Renna, Rosaria and Strigaro, Gionata and COMPARE Study Group, COMPARE Study Group and Russo, Emilio},
title = {A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.17843}
}
EUVIMED